Ana Chocarro-Calvo

Ana Chocarro-Calvo

Auto-generated profile, based on publicly available information

Ana Chocarro-Calvo

Area of Physiology, Faculty Health Sciences, University Rey Juan Carlos, 28922, Alcorcón, Madrid, Spain.

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Molecular Cell
Verified
Journal Article
Closed access
ACAna Chocarro-Calvo
Ana Chocarro-Calvo
JGJose Manuel García-Martínez
Jose Manuel García-Martínez
SASoraya Ardila-González
Soraya Ardila-González
AVAntonio De La Vieja
Antonio De La Vieja
CGCustodia García-Jiménez
Custodia García-Jiménez

18 September 2013 in Journal of Molecular Endocrinology
Verified
Journal Article
Closed access
CGCustodia García-Jiménez
Custodia García-Jiménez
JGJose Manuel García-Martínez
Jose Manuel García-Martínez
ACAna Chocarro-Calvo
Ana Chocarro-Calvo
AVAntonio De La Vieja
Antonio De La Vieja
Extensive epidemiological studies suggest that the diabetic population is at higher risk of site-specific cancers. The diabetes–cancer link has been hypothesized to rely on various hormonal (insulin, IGF1, adipokines), immunological (inflammation), or metabolic (hyperglycemia) characteristics of the disease and even on certain treatments. Inflammation may have an important but incompletely understood role. As a growth factor, insulin directly, or indirectly through IGF1, has been considered the major link between diabetes and cancer, while high glucose has been considered as a subordinate cause. Here we discuss the evidence that supports a role for insulin/IGF1 in general in cancer, and the mechanism by which hyperglycemia may enhance the appearance, growth and survival of diabetes-associated cancers. High glucose triggers several direct and indirect mechanisms that cooperate to promote cancer cell proliferation, migration, invasion and immunological escape. In particular, high glucose enhancement of WNT/β-catenin signaling in cancer cells promotes proliferation, survival and senescence bypass, and represents a previously unrecognized direct mechanism linking diabetes-associated hyperglycemia to cancer. Increased glucose uptake is a hallmark of tumor cells and may ensure enhanced WNT signaling for continuous proliferation. Mechanistically, high glucose unbalances acetylation through increased p300 acetyl transferase and decreased sirtuin 1 deacetylase activity, leading to β-catenin acetylation at lysine K354, a requirement for nuclear accumulation and transcriptional activation of WNT-target genes. The impact of high glucose on β-catenin illustrates the remodeling of cancer-associated signaling pathways by metabolites. Metabolic remodeling of cancer-associated signaling will receive much research attention in the coming years. Future epidemiological studies may be guided and complemented by the identification of these metabolic interplays. Together, these studies should lead to the development of new preventive strategies for diabetes-associated cancers.

23 February 2016 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
CGCustodia García-Jiménez
Custodia García-Jiménez
MGMaría Gutiérrez-Salmerón
María Gutiérrez-Salmerón
ACAna Chocarro-Calvo
Ana Chocarro-Calvo
JGJose Manuel García-Martinez
Jose Manuel García-Martinez
ACAngel Castaño
Angel Castaño
AVAntonio De La Vieja
Antonio De La Vieja
Increasing evidence suggests a complex relationship between obesity, diabetes and cancer. Here we review the evidence for the association between obesity and diabetes and a wide range of cancer types. In many cases the evidence for a positive association is strong, but for other cancer types a more complex picture emerges with some site-specific cancers associated with obesity but not to diabetes, and some associated with type I but not type II diabetes. The evidence therefore suggests the existence of cumulative common and differential mechanisms influencing the relationship between these diseases. Importantly, we highlight the influence of antidiabetics on cancer and antineoplastic agents on diabetes and in particular that antineoplastic targeting of insulin/IGF-1 signalling induces hyperglycaemia that often evolves to overt diabetes. Overall, a coincidence of diabetes and cancer worsens outcome and increases mortality. Future epidemiology should consider dose and time of exposure to both disease and treatment, and should classify cancers by their molecular signatures. Well-controlled studies on the development of diabetes upon cancer treatment are necessary and should identify the underlying mechanisms responsible for these reciprocal interactions. Given the global epidemic of diabetes, preventing both cancer occurrence in diabetics and the onset of diabetes in cancer patients will translate into a substantial socioeconomic benefit.

1 January 2020 in Molecular Cell
Verified
Journal Article
Closed access
YVYurena Vivas-García
Yurena Vivas-García
PFPAOLA FALLETTA
PAOLA FALLETTA
JLJana Liebing
Jana Liebing
PLPakavarin Louphrasitthiphol
Pakavarin Louphrasitthiphol
YFYongmei Feng
Yongmei Feng
CGColin R. Goding
Colin R. Goding

7 July 2009 in Diabetologia
Verified
Journal Article
Closed access
PDF file
JGJ. M. García-Martínez
J. M. García-Martínez
ACA. Chocarro-Calvo
A. Chocarro-Calvo
CMC. M. Moya
C. M. Moya
CGC. García-Jiménez
C. García-Jiménez

31 August 2016 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
VMVictoria Morales
Victoria Morales
MGMaría Gutiérrez‐Salmerón
María Gutiérrez‐Salmerón
MBMoisés Balabasquer
Moisés Balabasquer
JOJosefa Ortiz‐Bustos
Josefa Ortiz‐Bustos
ACAna Chocarro‐Calvo
Ana Chocarro‐Calvo
RGRafael A. Garcia-Muñoz
Rafael A. Garcia-Muñoz